Objective To explore the clinical effect and value of sitagliptin phosphate combined with metformin in the treatment of patients with newly diagnosed type 2 diabetes mellitus(T2DM).Methods The clinical data of 70 patients with newly diagnosed T2DM admitted to Longyan First Hospital Affiliated to Fujian Medical University from April 2023 to April 2024 were retrospectively selected.According to different treatment regimens,they were divided into control group(metformin alone)and observation group(sitagliptin phosphate combined with metformin),with 35 cases in each group.The glucose metabolism indexes,insulin indexes,blood glucose compliance rate and total incidence of adverse reactions were compared between the two groups.Results After treatment,the fasting blood glucose,2-hour postprandial blood glucose and glycated hemoglobin A1c in the observation group were lower than those A1c in the control group,and the differences were statistically significant(all P<0.05).After treatment,the fasting insulin in the observation group was lower than that in the control group,and the glucagon-like peptide-1 was higher than that in the control group,and the differences were statistically significant(both P<0.05).The blood glucose compliance rate of the observation group was higher than that of the control group at 1 month,2 months and 3 months after treatment,and the differences were statistically significant(all P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion In the treatment of patients with newly diagnosed T2DM,sitagliptin phosphate combined with metformin can have a positive effect on the improvement of glucose me-tabolism index and insulin index,and can also significantly improve the blood glucose compliance rate without in-creasing adverse reactions.
Type 2 diabetes mellitusMetforminSiagliptin phosphate
维普
万方数据
